Literature DB >> 17913970

Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin.

Priscilla P How1, James H Fischer, Jose A Arruda, Alan H Lau.   

Abstract

BACKGROUND AND OBJECTIVES: Phosphate binders such as calcium salts or sevelamer, a cationic polymer, can markedly reduce absorption of oral ciprofloxacin. This randomized, open-label, two-way, crossover study examined the influence of the cation lanthanum on systemic ciprofloxacin exposure after oral administration. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Twelve patients randomly received in a crossover manner a single oral dose of ciprofloxacin 750 mg alone and plus lanthanum carbonate 1 g three times daily with meals for six doses, with a washout interval of 7 to 14 d. Serial blood and urine samples were collected for 24 h after ciprofloxacin administration, and ciprofloxacin concentrations were determined using reverse-phase HPLC. Pharmacokinetic parameters of ciprofloxacin were calculated by noncompartmental methods, and the effect of lanthanum on ciprofloxacin pharmacokinetic parameters was assessed using ANOVA.
RESULTS: Lanthanum decreased (P < 0.001) the mean ciprofloxacin area under the plasma concentration-time curve by 54% and the maximum plasma concentration by 56%. The 24-h urinary recovery of ciprofloxacin was reduced by 52% by lanthanum (P < 0.001). No statistically significant differences in ciprofloxacin time to maximum plasma concentration, elimination half-life, and renal clearance occurred between the two arms.
CONCLUSIONS: Lanthanum carbonate significantly reduces the systemic exposure to orally administered ciprofloxacin. Concomitant administration of both drugs should be avoided to prevent possible suboptimal response to ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913970     DOI: 10.2215/CJN.01580407

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  10 in total

Review 1.  Phosphate binders in patients with chronic kidney disease.

Authors:  Samuel Chan; Kenneth Au; Ross S Francis; David W Mudge; David W Johnson; Peter I Pillans
Journal:  Aust Prescr       Date:  2017-02-01

Review 2.  Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.

Authors:  Stephen J P Damment; Michael Pennick
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 3.  Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.

Authors:  Monique P Curran; Dean M Robinson
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

Review 4.  Pharmacokinetics and dosage adjustment in patients with renal dysfunction.

Authors:  Roger K Verbeeck; Flora T Musuamba
Journal:  Eur J Clin Pharmacol       Date:  2009-06-20       Impact factor: 2.953

5.  Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions.

Authors:  Manuel Kussmann; Alexander Ferth; Markus Obermüller; Petra Pichler; Markus Zeitlinger; Martin Wiesholzer; Heinz Burgmann; Wolfgang Poeppl; Gottfried Reznicek
Journal:  Sci Rep       Date:  2019-04-24       Impact factor: 4.379

6.  Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.

Authors:  Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

7.  Release behavior and toxicity profiles towards A549 cell lines of ciprofloxacin from its layered zinc hydroxide intercalation compound.

Authors:  Ahmad Faiz Abdul Latip; Mohd Zobir Hussein; Johnson Stanslas; Charng Choon Wong; Rohana Adnan
Journal:  Chem Cent J       Date:  2013-07-12       Impact factor: 4.215

8.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321

Review 9.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

Review 10.  Pharmacokinetics in children with chronic kidney disease.

Authors:  Anne M Schijvens; Saskia N de Wildt; Michiel F Schreuder
Journal:  Pediatr Nephrol       Date:  2019-08-02       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.